Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China

被引:4
|
作者
Dun, Changchang [1 ,2 ]
Yuan, Meiwen [2 ]
Zhao, Xuelian [2 ]
Hu, Shangying [2 ]
Arbyn, Marc [3 ]
Zhao, Fanghui [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Dept Populat Med, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Epidemiol,Canc Hosp, Beijing, Peoples R China
[3] Sci Inst Publ Hlth, Belgian Canc Ctr, Unit Canc Epidemiol, Brussels, Belgium
来源
CANCER MEDICINE | 2024年 / 13卷 / 11期
关键词
cervical cancer; HPV genotyping; pooled analysis; screening; triage; INTRAEPITHELIAL NEOPLASIA; RISK; WOMEN; PREVALENCE; INFECTION; METAANALYSIS; PERFORMANCE;
D O I
10.1002/cam4.7316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To assess the clinical values of extended human papillomavirus (HPV) genotyping in triage of high-risk HPV-positive women, focusing on the trade-off between cervical precancer detections and colposcopy referrals. Methods: A bivariate random-effects model was used to estimate the diagnostic accuracy of primary HPV screening with following triage strategies to detect cervical precancers: (i) partial genotyping for HPV16/18 combined with cytological testing at atypical squamous cells of undetermined significance threshold (used as the comparator), (ii) genotyping for HPV16/18/58/52, (iii) genotyping for HPV16/18/58/52/33, (iv) genotyping for HPV16/18/58/33/31, (v) genotyping for HPV16/18/58/52/33/31, and (vi) genotyping for HPV16/18/58/52/33/31/39/51. Internal risk benchmarks for clinical management were used to evaluate the risk stratification of each triage strategy. Results: A total of 16,982 women (mean age 46.1 years, range 17-69) were included in this analysis. For CIN3+ detection, triage with HPV16/18/58/33/31 genotyping achieved lower positivity (6.85% vs. 7.35%, p = 0.001), while maintaining similar sensitivity (91.35% vs. 96.42%, p = 0.32) and specificity (94.09% vs. 93.67%, p = 0.56) compared with the comparator strategy. Similar patterns were observed for CIN2+ detection. Women with a positive HPV16/18/58/33/31 genotyping test had high enough risk for CIN3+ for colposcopy referral, while the risk for women with a negative test was below the 1-year return decision threshold according to internal benchmarks. Conclusions: Our findings suggested extended HPV genotyping is of potential to be used as a triage technique integrated into HPV-based cervical cancer screening, leading to reduced need for colposcopy referral while maintaining similar disease detection and efficient risk stratification.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] CERVICAL CANCER SCREENING USING PRIMARY HUMAN PAPILLOMAVIRUS (HPV) TESTING IN MOZAMBIQUE: PRELIMINARY RESULTS OF THE CAPULANA STUDY
    Pontremoli Salcedo, M.
    Oliveira, C.
    Andrade, V.
    Baker, E.
    Changule, D.
    Rangeiro, R.
    Varon, M. L.
    Phoolcharoen, N.
    Mariano, A.
    dos Santos, B. X.
    Chalyamba, M.
    Macaringue, R. F.
    Manhica, S. M.
    Thomas, J. P.
    Munsell, M.
    Fregnani, J. H. T.
    Lorenzoni, C.
    Schmeler, K. M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A51 - A52
  • [22] Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial
    Cook, Darrel A.
    Krajden, Mel
    Brentnall, Adam R.
    Gondara, Lovedeep
    Chan, Tracy
    Law, Jennifer H.
    Smith, Laurie W.
    van Niekerk, Dirk J.
    Ogilvie, Gina S.
    Coldman, Andrew J.
    Warman, Rhian
    Reuter, Caroline
    Cuzick, Jack
    Lorincz, Attila T.
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (10) : 2587 - 2595
  • [23] A Technical Comparison of Human Papillomavirus Genotyping Assays from a Population-Based Cervical Cancer Screening in South Central Ethiopia
    Teka, Brhanu
    Gizaw, Muluken
    Firdawoke, Ededia
    Addissie, Adamu
    Sisay, Tesfamichael Awoke
    Schreckenberger, Carola
    Skof, Anna Sophie
    Thies, Sarah
    Mihret, Adane
    Kantelhardt, Eva Johanna
    Abebe, Tamrat
    Kaufmann, Andreas M.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2253 - 2263
  • [24] Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China (vol 11, pg 1160, 2010)
    Zhao, F-H
    Lin, M. J.
    Chen, F.
    LANCET ONCOLOGY, 2011, 12 (01): : 11 - 11
  • [25] Human Papillomavirus (HPV) Cervical Cancer Screening and Secondary Prevention in Cote d'Ivoire: Time From Testing to Treatment
    Gouesse, Rita-Josiane
    Dodo, Mathurin
    Kouassi, Jean-Claude
    Boni, Simon
    Setoh, Joel
    Zadi, Ida
    Bertram, Meg
    Shissler, Tracey
    Huang, Lisa
    Daceney, Nemdia
    Adoubi, Innocent
    Gauvreau, Cindy
    Kabue, Mark
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2023, 32 (06)
  • [26] AN UPDATED CLINICAL-ECONOMIC MODELING ANALYSIS OF CERVICAL CANCER SCREENING WITH HPV CO-TESTING VERSUS PRIMARY HPV TESTING
    Miller, J. D.
    Onyekwere, U.
    Lenhart, G. M.
    Vilalta, A.
    Troeger, K. A.
    VALUE IN HEALTH, 2020, 23 : S48 - S48
  • [27] Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China
    Pan, Qin-Jing
    Hu, Shang-ying
    Zhang, Xun
    Ci, Pu-wa
    Zhang, Wen-hua
    Guo, Hui-qin
    Cao, Jian
    Zhao, Fang-hui
    Lytwyn, Alice
    Qiao, You-lin
    CANCER CYTOPATHOLOGY, 2013, 121 (09) : 473 - 482
  • [28] Cervical cancer screening program integrating Pap smear and HPV DNA testing: A population-based study
    Chao, Angel
    Hsu, Kuang-Hung
    Lai, Chyong-Huey
    Huang, Huei-Jean
    Hsueh, Swei
    Lin, Sheue-Rong
    Jung, Shih-Ming
    Chao, Fang-Yu
    Huang, Shang-Lang
    Huang, Chu-Chun
    Yang, Jung-Erh
    Chang, Ting-Chang
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (12) : 2835 - 2841
  • [29] Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China
    Zhang, Jing
    Yang, Di
    Cui, Xiaoli
    Liu, Guangcong
    Cui, Zhumei
    Wang, Chunyan
    Piao, Haozhe
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [30] Effect of introducing human papillomavirus genotyping into real-world screening on cervical cancer screening in China: a retrospective population-based cohort study
    Dong, Binhua
    Zou, Huachun
    Mao, Xiaodan
    Su, Yingying
    Gao, Hangjing
    Xie, Fang
    Lv, Yuchun
    Chen, Yaojia
    Kang, Yafang
    Xue, Huifeng
    Pan, Diling
    Sun, Pengming
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13